CB2 Receptor Loss Linked to Trastuzumab Resistance in HER2-Positive Breast Cancer
Researchers have identified that a reduction in the expression of the CB2 cannabinoid receptor (CB2R) is linked to poorer clinical outcomes and increased relapse risk in patients with HER2-positive breast cancer. A study published in Oncogene by the Universidad Complutense de Madrid and the Instituto de Investigación Sanitaria Hospital 12 de Octubre found that this protein deficiency enables tumor cells to activate alternative growth pathways, effectively resisting trastuzumab, the standard therapy for this cancer type.
Understanding the Role of CB2R in Treatment Resistance
The CB2 receptor is a protein within the endocannabinoid system responsible for modulating the immune system and managing inflammation. According to research led by Cristina Sánchez of the UCM Department of Biochemistry and Molecular Biology, the loss of this protein during early treatment stages allows cancer cells to bypass the immune mechanisms that typically support the efficacy of trastuzumab.
This study marks the first time the endocannabinoid system has been directly implicated in resistance to anti-tumor treatments. Beyond the loss of CB2R, investigators identified a compensatory activation of the EGFR receptor, which further contributes to tumor progression and survival despite the presence of standard therapies.
The endocannabinoid system, which helps regulate the body’s internal balance, had long been understood to participate in cancer biology, but its specific role in driving resistance to clinical anti-tumor treatments remained unproven until this 2026 study.
Potential Clinical Applications
The research team utilized a combination of preclinical models—including cellular and animal studies—and tumor samples from patients treated at hospitals in Madrid, including the 12 de Octubre and Puerta de Hierro-Majadahonda. These findings suggest two primary paths for future clinical application. First, CB2R could function as a biomarker to screen patients early, identifying those at high risk for developing resistance to trastuzumab.
Second, the findings point toward new therapeutic strategies for high-risk patients. These could include the combined use of HER2 and EGFR inhibitors or the administration of specific cannabinoids, which have demonstrated anti-tumor effects in preclinical models that were otherwise resistant to trastuzumab.
The identification of CB2R as a predictive marker shifts the focus of oncology toward more precise, personalized interventions. By recognizing that tumors may switch to alternative receptors like EGFR when CB2R is lost, clinicians may eventually move toward combination therapies that block these “escape routes” before the cancer has a chance to progress.
What Happens Next
While these results offer a new understanding of HER2-positive breast cancer, further validation is required before these methods reach standard clinical practice. According to researchers, the next steps involve additional studies to confirm these findings in broader patient populations. If validated, these strategies could lead to more effective, tailored treatment plans designed to overcome the limitations of current anti-HER2 therapies.
Frequently Asked Questions
What is the primary function of the CB2 receptor?
The CB2 receptor is a protein in the endocannabinoid system that helps regulate the immune system and reduce inflammation in the body.
Why do some HER2-positive breast cancer patients relapse?
Relapse is linked to the reduction of CB2R expression, which allows tumor cells to activate alternative growth pathways and escape the immune mechanisms that trastuzumab normally triggers.
How could this study change future treatments?
It may allow doctors to use CB2R as a biomarker to predict treatment resistance early and could lead to new combination therapies, such as using HER2 and EGFR inhibitors together.
How might these findings change the way oncologists approach early-stage breast cancer screening?